Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats

Area of Science:

• Nuclear Medicine
• Oncology
• Radiology

Background:

• Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) is crucial in Hodgkin lymphoma management.
• Established for initial staging and end-of-treatment response evaluation.
• The role of interim FDG-PET for early response assessment and treatment tailoring is debated.

Purpose of the Study:

• To evaluate the evolving role of interim FDG-PET in Hodgkin lymphoma.
• To discuss its potential for treatment reduction in good responders and adaptation in poor responders.
• To review current interpretation methods and ongoing research.

Main Methods:

• Review of current literature and expert meeting guidelines (Deauville 2009).
• Discussion of visual versus quantitative interpretation of interim FDG-PET.
• Highlighting ongoing prospective randomized trials for localized and advanced disease.

Main Results:

• Interim FDG-PET can guide treatment reduction or adaptation.
• Visual interpretation is currently favored over quantitative methods.
• The concept of minimal residual uptake has evolved.
• Guidelines for interpretation exist, but further validation is needed.

Conclusions:

• Interim FDG-PET holds potential for early treatment monitoring and tailoring in Hodgkin lymphoma.
• Treatment changes based on interim PET results should be limited to clinical trials until prospective data are available.
• Further research is essential to solidify the role of interim FDG-PET in clinical practice.